Presentation

Senzime is a Swedish medical technology company that develops and markets CE-marked and FDA-cleared patient monitoring systems. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications and reduce health care costs related to surgical and high acuity procedures.

Recent highlights
In Q2, net sales amounted to 3.4M SEK (-22.5%).
In February, Senzime announced that the company has won an order from a large American university hospital regarding the placement of 50 TetraGraph systems. In March, Senzime won another procurement for 23 TetraGraph systems and an order with an initial value exceeding SEK 1 million, both from hospitals in the US. In the same month, Senzime received CE-MDR approval for the new single-us sensor TetraSens Pediatric for use on young children. In June, Senzime carried out a directed new issue of approximately SEK 100M. In the same month, Senzime signed strategic connectivity and licensing agreements with Masimo, a US and globally leading company in patient monitoring solutions. In July, Senzime completed the acquisition of the American company Respiratory Motion, Inc. In August, Senzime received FDA 510k-clearance for use in children with the disposable sensor TetraSens Pediatric.

Outlook
With strong organic growth, a strategic partnership with a global leader and a recent acquisition, the company expects continued high business activity in the future.